Home > Insider Trading > Filing (0001209191-19-010320)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1708493	Harpoon Therapeutics Inc.	HARP	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1687078	Mpm Oncology Impact Management Lp	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1691428	L.p. Fund Impact Oncology Ubs	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1721035	Mpm Oncology Impact Management Gp Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1721036	L.p. Management (Cayman) Fund Impact Oncology	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-02-12	1,525,165	$0.00	1,525,165	No	4	C	Direct
Common Stock	Acquisiton	2019-02-12	1,578,755	$0.00	3,103,920	No	4	C	Direct
Common Stock	Acquisiton	2019-02-12	417,853	$0.00	3,521,773	No	4	C	Direct
Common Stock	Acquisiton	2019-02-12	127,096	$0.05	3,648,869	No	4	X	Direct
Common Stock	Disposition	2019-02-12	447	$14.00	3,648,422	No	4	S	Direct
Common Stock	Acquisiton	2019-02-12	250,000	$14.00	3,898,422	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	X	Direct
No	4	S	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-02-12	1,525,165	$0.00	1,525,165	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-02-12	1,578,755	$0.00	1,578,755	$0.00
Common Stock	Series C Preferred Stock	Disposition	2019-02-12	417,853	$0.00	417,853	$0.00
Common Stock	Common Stock Warrant (Right to Buy)	Disposition	2019-02-12	76,258	$0.00	76,258	$0.05
Common Stock	Common Stock Warrant (Right to Buy)	Disposition	2019-02-12	50,838	$0.00	50,838	$0.05

Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
		No	4	C	Direct
		No	4	C	Direct
		No	4	C	Direct
2016-11-01	2026-11-01	No	4	X	Direct
2017-01-10	2027-01-10	No	4	X	Direct

Footnotes

All series of convertible preferred stock will automatically convert into the number of shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer'sinitial public offering and have no expiration date.
The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the Managing Member of Oncology GP LLC.
The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
On February 12, 2019, UBS Oncology exercised warrants to purchase an aggregate of 127,096 shares of the Issuer's common stock for $0.0492 per share. UBS Oncology paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 447 of the warrant shares to pay the exercise price and issuing to UBS Oncology the remaining 126,649 shares.